Ask AI
ProCE Banner Activity

Translating Progress Into Practice: Optimizing MS Treatment and Patient Outcomes

Clinical Thought

This ClinicalThought commentary explores the evolving understanding of multiple sclerosis as a spectrum disorder driven by a dual immunopathologic process present early in the disease and highlights implications for diagnosis, progression, treatment gaps, and the growing need for biologically informed, multidisciplinary approaches to optimize long-term outcomes.

Released: January 12, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Target Audience

This activity is intended for healthcare professionals in neurology who provide care for patients with MS, including physicians, nurse practitioners, physician associates, and pharmacists. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify the immunopathogenic mechanisms and biologic basis of MS in the context of available treatment options

Disclosure

Primary Author

Patricia K. Coyle, MD, FAAN, FANA: consultant/advisor/speaker: Accordant, Amgen, GSK, Horizon Therapeutics, Novartis, Sanofi Genzyme; researcher: CorEvitas, Genentech/Roche, Sanofi Genzyme.